The moral imperative: Balancing innovation, regulation and prescription drug availability

Update: 2022-03-21

Description

DLA Piper's Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky, founding Partner and Portfolio Manager at RA Capital, to discuss the importance of – and complications in – balancing biopharmaceutical innovation, industry regulations and prescription drug availability.

See omnystudio.com/listener for privacy information.

Comments

In Channel

Revolutionizing Clinical Trials: A discussion on diversity and patient-centric approaches

2024-11-1529:38

Life sciences companies and the risks posed by the mifepristone litigation

2023-05-1933:18

Trade secrets protection in the life sciences sector

2023-04-1221:23

Cross-border considerations for privacy in clinical trials

2023-02-0618:19

Global Life Sciences Supply Chain Insights

2022-11-0327:36

AI risk assessments: Future-proofing your innovation when rules can change mid-game

2022-09-0624:43

The rise of global telehealth

2022-06-0125:35

Advising the advisor: Tips for navigating the life sciences and regulatory environment

2022-04-1831:00

The moral imperative: Balancing innovation, regulation and prescription drug availability

2022-03-2130:31

Incentivizing diverse representation in clinical trials

2022-03-0222:40

The crossroad of science and law

2021-12-1626:17

Social media’s impact on the life sciences industry

2021-11-0834:50

Understanding AI and its use in drug discovery

2021-10-0531:49

mRNA technology and the COVID-19 vaccine: A conversation with Pfizer’s Kathy Fernando

2021-09-0326:25

00:00

The moral imperative: Balancing innovation, regulation and prescription drug availability

#box-pro-ellipsis-175757399253165{-webkit-line-clamp:2;}The moral imperative: Balancing innovation, regulation and prescription drug availability

The moral imperative: Balancing innovation, regulation and prescription drug availability

DLA Piper

The moral imperative: Balancing innovation, regulation and prescription drug availability